AgingResearch.NewsJoin free

Fibrocor Therapeutics

CompanyCanada

Fibrocor Therapeutics develops 3 assets, the furthest preclinical (FIB918). Mostly small molecule and antibody; based in Canada.

3
Assets
Furthest stage
Preclinical
0
Trials
0
Signals

Pipeline

3

  • FIB918

    Antagonizes a protein involved in myofibroblast differentiation and function.

    Preclinical, Antibody

  • FIB991

    Blocks the YAP/TAZ pathway, shutting down fibroblast activation and stopping fibrosis progression.

    Preclinical, Small molecule, ADPKD, kidney allograft fibrosis

  • FIB992

    Inhibits a novel kinase target in the matrix stiffness pathway, decreasing secretion of profibrotic cytokines.

    Preclinical, Small molecule, Alport syndrome

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • People3
  • Similar companies6

Intelligence